Influenza

Join Clinical Trials for Influenza (Flu)

Join Clinical Trials for Influenza (Flu)

General Purpose: Anyone who has ever had the flu knows that it can be a scary illness. Although sometimes its symptoms can be mild and impactful for only a few days, at other times it can be severe, and even deadly.

Fortunately, research pertaining to the viruses that cause the flu has provided valuable insight into their behavior both in the environment around us as well as within our bodies; however, the viruses continue to change, or mutate, making current vaccination all the more important, and driving the need for continued research to keep pace with this ever-changing entity.

As such, flu-related research focuses on a multitude of topics, including monitoring the viruses as they spread locally, nationally, and globally, evaluating the effectiveness of various flu vaccines, focusing on issues specific to high-risk populations (i.e., pregnant women, children, and the elderly), and new methods to prevent and treat infections.

Continued … Influenza Clinical Trials (Click to Open)

Join Clinical Trials for Influenza (Flu)

Influenza Clinical Trials

What Will Clinical Trials for Influenza Be Like?

When participating in Clinical Trials for Influenza, a few common tests and procedures may be involved; however, the ultimate design of the particular study will determine which Influenza Clinical Trialsspecific procedures you will undergo.

On a basic level, flu-related research studies might require multiple blood tests to detect the presence of the flu virus and changing levels of the virus in response to treatments. Others may involve the use of vaccinations followed by short-term monitoring (i.e., throughout the duration of a normal flu season).

Some studies may evaluate the effectiveness of various preventive measures, such as frequent hand washing, disinfecting, wearing of respiratory masks, and the use of vitamin supplements to boost the immune system.

Typical Flu Clinical Trial Protocol:

Research related to the flu is widespread and deep. Specific examples might include the following types of studies:

  • A study designed to investigate methods to refine diagnostic tools for the flu so that individual flu strains (i.e., viruses) can be identified quicker and more accurately. Studies such as these are especially important in light of concerns of a potential global flu outbreak.
  • Studies designed to develop new anti-viral medications to treat the flu.
  • A trial designed to determine the effectiveness of specific drug combinations at treating the flu.
  • A trial designed to determine how accurately certain drugs target specific portions of the flu virus, which can help to prevent drug resistance as well as uncover reasons why certain flu viruses become resistant to common treatments.
  • A study designed to evaluate the effectiveness of a vaccine targeted toward newly emerging flu viruses.
  • A study designed to evaluate the effectiveness of flu vaccines in special populations, such as children, the elderly, and individuals with chronic conditions like diabetes or cancer.

Suggested Search Terms:

“influenza vaccine,” “influenza pregnancy,” “influenza pregnancy,” “influenza elderly,” “influenza treatment,” and “influenza prevention.” 

Current Search Term:

“Influenza”



Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine


Condition:   Influenza
Interventions:   Biological: Multi-dose Quadrivalent Influenza Vaccine;   Biological: Single-dose Quadrivalent Influenza Vaccine
Sponsor:   Sanofi Pasteur, a Sanofi Company
Recruiting


Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years


Conditions:   Influenza;   Flu
Interventions:   Biological: SP Shz TIV;   Biological: Hualan TIV
Sponsor:   Sanofi
Recruiting


A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza


Condition:   Influenza
Interventions:   Drug: Nitazoxanide;   Drug: Placebo
Sponsor:   Romark Laboratories L.C.
Not yet recruiting


Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines


Conditions:   Influenza;   Flu
Interventions:   Biological: Fluzone Quadrivalent vaccine;   Biological: Fluzone High-Dose vaccine
Sponsor:   Sanofi Pasteur, a Sanofi Company
Completed


Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US


Condition:   Influenza
Interventions:   Biological: QIV-HD;   Biological: Licensed TIV-HD1;   Biological: Investigational TIV-HD2
Sponsor:   Sanofi Pasteur, a Sanofi Company
Active, not recruiting


Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years


Condition:   Influenza
Interventions:   Biological: QIV-HD by IM;   Biological: QIV-SD by SC;   Biological: QIV-HD by SC
Sponsors:   Sanofi Pasteur, a Sanofi Company;   Sanofi K.K.
Completed


Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)


Condition:   Influenza
Interventions:   Biological: Fluzone®;   Biological: FluMist®
Sponsors:   Stanford University;   National Institute of Allergy and Infectious Diseases (NIAID)
Terminated


The Human Mucosal Immune Responses to Influenza Virus (SLVP026)


Condition:   Influenza
Interventions:   Biological: Fluzone®;   Biological: FluMist®
Sponsors:   Stanford University;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed


Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)


Condition:   Influenza
Interventions:   Biological: Fluzone®;   Biological: FluMist®
Sponsors:   Stanford University;   National Institute of Allergy and Infectious Diseases (NIAID)
Terminated


B-cell Immunity to Influenza (SLVP017)- Year 5, 2013


Condition:   Influenza
Intervention:   Biological: Fluzone
Sponsors:   Stanford University;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed


Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age


Condition:   Influenza
Intervention:   Biological: 2008-2009 FluMist LAIV (Intranasal)
Sponsors:   Stanford University;   National Institute of Allergy and Infectious Diseases (NIAID)
Terminated


Prospective Analysis of Seasonal Influenza - Viral Transmission and Evolution in the City of Basel, Switzerland


Condition:   Influenza
Intervention:  
Sponsors:   University Hospital, Basel, Switzerland;   Swiss Federal Institute of Technology;   University Children's Hospital Basel;   University of Basel
Active, not recruiting


A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)


Condition:   Influenza
Interventions:   Biological: Live-Attenuated influenza Vaccine(LAIV);   Biological: Placebo
Sponsors:   Changchun BCHT Biotechnology Co.;   Beijing Simoonrecord Pharma information Consulting Co, Ltd;   National Institutes for Food and Drug Control, China;   Baoding Municipal Center for Disease Control and Prevention, Hebei, P.R.China;   Zhejiang Provincial Center for Disease Control and Prevention, P.R.China;   Maoming Municipal Center for Disease Control and Prevention, Guangdong, P.R.China;   Department of Medical Statistics, Fourth Military Medical University
Completed


Phase 3 Trial of Serbian Seasonal Influenza Vaccine


Condition:   Influenza
Interventions:   Biological: Seasonal Influenza Vaccine;   Other: Phosphate Buffered Saline
Sponsors:   Institute of Virology, Vaccines and Sera, Torlak;   PATH;   Comac Medical;   World Health Organization
Completed


Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations


Condition:   Influenza
Interventions:   Biological: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative;   Biological: Fluzone High-Dose, vaccine, 2016-2017 formulation
Sponsor:   Sanofi Pasteur, a Sanofi Company
Completed


Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease


Condition:   Influenza
Interventions:   Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);   Biological: H3N2v inactivated subvirion influenza vaccine;   Biological: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting


Influenza Immunity in Children


Condition:   Influenza
Interventions:   Biological: Seasonal IIV;   Other: Natural influenza infection
Sponsor:   University of Rochester
Active, not recruiting


A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older


Condition:   Influenza
Interventions:   Biological: High-dose quadrivalent influenza virus vaccine;   Biological: High-dose influenza virus vaccine;   Biological: High-dose trivalent inactivated influenza vaccine
Sponsor:   Sanofi Pasteur, a Sanofi Company
Completed


Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India


Condition:   Influenza
Intervention:   Biological: Quadrivalent Inactivated Influenza Vaccine, No Preservative
Sponsor:   Sanofi Pasteur, a Sanofi Company
Completed


Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects


Condition:   Influenza A
Interventions:   Drug: VX-787 300 mg;   Drug: VX-787 600 mg;   Drug: Oseltamivir 75 mg;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Pharmaceuticals
Completed


Inactivated Influenza Via Jet Injection


Condition:   Influenza, Human
Intervention:   Biological: Influenza Vaccine
Sponsor:   PharmaJet, Inc.
Completed


Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age


Condition:   Influenza
Interventions:   Biological: Flublok Quadrivalent Influenza Vaccine;   Biological: Inactivated Influenza Vaccine
Sponsor:   Protein Sciences Corporation
Completed


Self-Administered Nasal Influenza Feasibility Study


Condition:   Influenza
Intervention:   Drug: FluMist
Sponsor:   Uniformed Services University of the Health Sciences
Completed


Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza


Condition:   Influenza
Interventions:   Drug: 40 mg Laninamivir Octanoate;   Drug: 80 mg Laninamivir Octanoate;   Drug: Placebo
Sponsors:   Biota Scientific Management Pty Ltd;   Department of Health and Human Services
Completed


Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza


Condition:   Influenza
Interventions:   Drug: Nitazoxanide;   Drug: Oseltamivir;   Drug: Placebo Oral Tablet;   Drug: Placebo Oral Capsule
Sponsor:   Romark Laboratories L.C.
Completed

Refine Your Search Advanced Search